The omega-3 index as a biomarker of health
The omega-3 index measures the percentage of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in red blood cell membranes, expressed as a percentage of total fatty acids. Unlike a single blood test that captures a moment in time, the omega-3 index reflects dietary intake over the preceding two to three months, making it a stable, reliable biomarker for long-term omega-3 consumption and tissue status.
Research consistently demonstrates that a higher omega-3 index correlates with improved cardiovascular outcomes, better cognitive function, and reduced inflammation markers. The index is now used in clinical practice and population health studies to assess cardiac risk, stratify patients for intervention, and monitor the effectiveness of omega-3 supplementation or dietary modification programmes.
Regional variation: Japan's omega-3 advantage
Japanese populations demonstrate the highest omega-3 indices in the Asia-Pacific region, with mean EPA and DHA levels substantially above international reference ranges. This advantage stems from a traditional diet centred on fatty fish — mackerel, sardines, salmon — consumed multiple times weekly, supplemented by nori seaweed and other marine sources. Blood testing data from Japanese cohorts consistently shows omega-3 indices exceeding 8-10%, well into the protective range associated with cardiovascular health.
However, even in Japan, younger urbanised populations consuming more Western processed foods show declining omega-3 levels compared to older generations. This generational shift signals that dietary tradition alone cannot sustain optimal omega-3 status in the face of globalised food systems emphasising convenience over nutritional density.
Southeast Asia: Variable deficiency amid dietary transition
Southeast Asian countries present a more complex picture. Populations with continued access to fresh seafood — coastal regions of Vietnam, Thailand, and Indonesia — maintain moderate omega-3 indices through abundant fish consumption. However, inland and urban populations increasingly rely on processed foods, livestock meat, and vegetable oils high in omega-6 linoleic acid, which compete metabolically with omega-3 pathways.
Blood testing reveals that omega-3 deficiency is emerging as a public health issue in urban Southeast Asia, particularly in rapid-growth cities where traditional fish-based meals have been displaced by convenient, imported processed foods. A shift from fresh fish to canned meat products and ultra-processed snacks has created a generation with critically low EPA and DHA levels, increasing cardiovascular and metabolic risk in populations still relatively young.
Australia and New Zealand: Moderate status and mixed influences
Australian and New Zealand populations demonstrate moderate omega-3 indices, typically in the range of 5-7%, reflecting a mix of Western dietary patterns with growing consumer awareness of omega-3 benefits. Seafood consumption is regular but not the dietary staple it is in Japan; compensatory supplements and fortified foods partially offset naturally lower dietary intake.
These countries benefit from established healthcare infrastructure and consumer access to high-quality omega-3 supplements, enabling interested individuals to optimise their levels. However, population-level testing shows that without active intervention or dietary prioritisation, baseline omega-3 deficiency is common. The relatively mature supplement market has created a bifurcation: informed, health-conscious consumers with adequate omega-3 status, and a broader population with marginal or low levels.
Cardiovascular risk and the urgency of population screening
The omega-3 index is now recognised by the American Heart Association and other major cardiovascular organisations as an independent risk factor. An index below 4% is associated with elevated sudden cardiac death risk; indices above 8% are protective. Population studies across Asia-Pacific reveal that the majority of urban and peri-urban populations fall into intermediate or low-risk categories, with many well below 4%.
For healthcare professionals and public health agencies, omega-3 deficiency in Asia-Pacific represents a modifiable risk factor that remains largely unscreened and unaddressed. DBS (dried blood spot) omega-3 testing makes large-scale population screening feasible, enabling early identification of at-risk individuals before clinical events occur. Masdiag's Omega-3 Index & Fatty Acid Profile test allows health systems and wellness programmes to measure regional baseline prevalence and track intervention outcomes.
Wellness brands and product development opportunities
Supplement and wellness brands operating across Asia-Pacific can use omega-3 blood testing data to inform regional product strategy and substantiate claims. Testing provides objective evidence of baseline deficiency in target markets, validation of product efficacy through before-and-after customer cohorts, and insights into which regional populations have the greatest unmet need for intervention.
Brands increasingly partner with diagnostic laboratories to offer customer testing as part of wellness programmes, enabling personalised recommendations and differentiated product positioning. In markets like Southeast Asia and urban China, where omega-3 deficiency is prevalent but awareness is still emerging, structured testing and education programmes create both market opportunity and genuine public health impact. The data itself becomes a marketing asset, demonstrating real-world impact on measurable biomarkers.
Frequently asked questions
What is the omega-3 index and why does it matter?
The omega-3 index measures the percentage of EPA and DHA in red blood cell membranes, reflecting long-term omega-3 intake over the previous 2-3 months. A higher index correlates with reduced cardiovascular risk. Population studies across Asia-Pacific show significant regional variation, with Japan typically maintaining higher indices due to traditional fish-rich diets, while Southeast Asian populations often show lower values as Western processed foods replace traditional seafood consumption.
How do EPA and DHA levels differ across Asia-Pacific regions?
Blood testing reveals distinct patterns: Japan maintains the highest EPA/DHA levels due to high seafood consumption, Australian and New Zealand populations show moderate levels reflecting mixed Western and Mediterranean-influenced diets, while Southeast Asian countries show variable levels depending on continued access to fresh seafood versus increasing urbanisation and processed food consumption. These variations reflect both cultural dietary traditions and economic transitions in the region.
How can wellness brands use omega-3 testing data?
Wellness brands can use Masdiag's Omega-3 Index & Fatty Acid Profile test to establish baseline population data, segment customers by omega-3 status, track product efficacy through before-and-after testing, and develop targeted supplementation strategies. Blood testing provides objective evidence for marketing claims and helps brands understand regional demand for omega-3 products based on actual deficiency prevalence in specific markets.
Explore This Test
View the full method details, sample requirements, and analytical specifications for our Omega-3 Index & Fatty Acid Profile test.
View Omega-3 Index Method →